Janssen Pharmaceutica
Records under this name other than patents Janssen Pharmaceutica holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,765,979 | Synthesis of (2S-CIS)-2-(BROMOMETHYL)-2-(4-Chlorophenyl)-1,3 DIOXOLANE-4-Methanol Methanesulfonate(ESTER) Lapsed on the fee record Ended Jul 1, 2026 · High confidence | Lapsed on the fee record | Ended Jul 1, 2026 | High confidence |
| US 8,653,099 | Cold Menthol Receptor Antagonists Lapsed on the fee record Ended Feb 18, 2026 · High confidence | Lapsed on the fee record | Ended Feb 18, 2026 | High confidence |
| US 8,552,032 | Bicyclic derivatives useful as inhibitors of DPP-1 Lapsed on the fee record Ended Oct 8, 2025 · From the USPTO record | Lapsed on the fee record | Ended Oct 8, 2025 | From the USPTO record |
| US 7,585,861 | HIV Inhibiting 1,2,4-Triazines Formerly held Term ended Term ended May 13, 2024 · High confidence | Term ended | Term ended May 13, 2024 | High confidence |
| US 9,255,103 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES PYRAZOLE ANALOGS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS Formerly held Lapsed on the fee record Ended Feb 9, 2024 · High confidence | Lapsed on the fee record | Ended Feb 9, 2024 | High confidence |
| US 9,029,366 | Substituted Bicyclic Alkoxy Pyrazole Analogs as Allosteric Modulators of MGLUR5 Receptors Formerly held Lapsed on the fee record Ended May 12, 2023 · High confidence | Lapsed on the fee record | Ended May 12, 2023 | High confidence |
| US 7,892,779 | Method of determining chymase activity with secretory leukocyte protease inhibitor Formerly held Lapsed on the fee record Ended Feb 22, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 22, 2023 | From the USPTO record |
| US 7,892,826 | Human cell clones having an endogeneous urotensin II receptor Formerly held Lapsed on the fee record Ended Feb 22, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 22, 2023 | From the USPTO record |
| US 7,125,891 | Tripeptidyl peptidase inhibitors Formerly held Term ended Term ended Aug 28, 2022 · From the USPTO record | Term ended | Term ended Aug 28, 2022 | From the USPTO record |
| US 8,703,946 | Substituted Pyrazolo[1,5-a]pyrazine Compounds as Allosteric Modulators of MGLUR5 Receptors Formerly held Lapsed on the fee record Ended Apr 22, 2022 · High confidence | Lapsed on the fee record | Ended Apr 22, 2022 | High confidence |